Page 199 - Read Online
P. 199

Chen et al. Mini-invasive Surg 2018;2:43  I  http://dx.doi.org/10.20517/2574-1225.2018.42                                          Page 9 of 12


                    Positive   CRM   (%)   5  2.4  1.9  0.9  16.1  4  5  11.7  0  5.0  6.8  0  1.5  6.9  3.6  0  0  NA  0  5.5




                      DRM (cm)  1.9 (1-4)  3.6 (0.4-10)  2.8  3.0 ± 2.0  2.2 ± 1.5  1.7 ± 1.4 (0.1-6.0)  3.5 ± 2.7 (0.1-16.3)  3.1 ± 1.7  2.5 (0.5-10)  2.0 ± 1.4  2.75 ± 2.14 (1-14)  2.7 (1.6-4.4)  1.8 (0-22.0)  2.6 ± 1.4  2.7 (0.4-8.0)  2.65 (0.4-7.5)  2.5 ± 1.3 (0.6-5.5)  2.8 ± 1.9  2.96 ± 2.05  NA





                     Rate of sphincter   preservation (%)  93.3  85.4  100  NA  93.9  97.3  79.2  93.4  100  100  100  86.2  93.5  99.2  88.0  84.6  75.0  95.1  85  100





                     Anastomotic   leakage (%)  3.3  7.3  9.6  8.7  NA  5.4  6.3  5  5.7  10.4  4.5  7.1  9.5  7.7  2  12.1  NA  1.5  8  7.2





                     Overall com-  plications (%)  21.7  22.0  19.2  40.2  45.6  16.2  28.7  15  26.4  25.9  19.7  41.5  38.5  24.6  49  NA  9  42  25.5




                     Estimated blood   loss (mL)  95  200 (20-2000)  NA  119 ± 164  232.0 ± 180.0  180 ± 28.1   (0-1100)  190 ± 128  74.2 ± 50  60.8 (0-400)  179.0 ± 236.5  77.6 ± 153.2   (0-700)  0 (0-175)  190 (0-1500)  245.7 ± 222.1   (10.0-1300.0)  10 (0-200)  200 (25-6000)  68 ± 138 (0-600)  15.4 ± 26.4  296 ± 155  NA

                Table 4. Comparison of clinical and perioperative outcomes of robotic-assisted total mesorectal excision



                     Lower rectum  Preoperative  Conversion   Rate (%)  CCRT (%)  (%)  0  81.7  100  7.3  80.5  36.6*  0  23.1  60.4 #  5.9  51.3  31.3  6.1  100  NA  1.4  100  NA  4  74.3  28.7  0  36.7  56.7*  3.8  49.1  NA  0.4  32.7  24.8  0  11.3  24.8  1.5  72.3  100 #  0  27.5  56.5  0.8  21.1  26.8  0  21.7  NA  2.6  84.6  53.9 #  0  0  NA  0  0.5  60.1 #  12  58  NA  0  45.4  100 *< 7 cm;  # extraperitoneal. CCRT: concurrent chemoradiotherapy; CRM: circumferentia

















                      Sample size  60 (yp Stage 0-III)  41 (yp Stage 0-III)  52 (yp Stage 0-III)  425 (yp Stage I-IV)  33 (yp Stage 0-III)  74 (yp Stage 0-III)  101 (yp Stage 0-IV)  60 (yp Stage 0-IV)  53 (yp Stage (yp 0-III)  278 (yp Stage 0-III)  133 (yp Stage I-III)  65 (yp Stage 0-III)  200 (yp Stage 0-IV)  370 (yp Stage 0-IV)  83  39 (yp Stage I-IV)  28 (yp Stage I-IV)  203 (yp Stage 0-IV)  26  55







                     Country   (year)   Taiwan   (2018)  Korea   (2011)  Korea   (2011)  USA   (2015)  Korea   (2016)  Korea   (2013)  USA   (2015)  Korea   (2016)  Italy   (2016)  Korea   (2012)  Korea   (2015)  Brazil/Italy   (2014)  Korea   (2014)  Korea   (2013)  UK   (2016)  USA   (2007)  Italy   (2009)  Japan   (2016)  Canada   (2016)  Egypt   (2014)






                         Present study  Baek et al. [11]  Park et al. [12]    Hellan et al. [14]  Kim et al. [23]  Saklani et al. [24]  Pai et al. [29]  Kim et al. [30]  Feroci et al. [31]  Cho et al. [32]  Park et al. [33]  Ghezzi et al. [34]  Hara et al. [35]  Baik et al. [36]  Ahmed et al. [37]  Hellan et al. [38]  Luca et al. [39]  Yamaguchi et al. [40]  Ramji et al. [41]  Abdel-Gawad et al. [42]

                      Study
   194   195   196   197   198   199   200   201   202   203   204